Department of Health and Human Services, Public Health Service, National Institutes of Health. Recombinant DNA Advisory Committee, Points to Consider Subcommittee. Minutes of meeting, March 31, 1989.
出版信息
Recomb DNA Tech Bull. 1989 Sep;12(3):151-70.
PMID:2595016
Abstract
摘要
相似文献
1
Department of Health and Human Services, Public Health Service, National Institutes of Health. Recombinant DNA Advisory Committee, Points to Consider Subcommittee. Minutes of meeting, March 31, 1989.卫生与公众服务部，公共卫生服务局，国立卫生研究院。重组DNA咨询委员会，要点审议小组委员会。1989年3月31日会议记录。
Recomb DNA Tech Bull. 1989 Sep;12(3):151-70.
2
Department of Health and Human Services, Public Health Service, National Institutes of Health. Recombinant DNA Advisory Committee. Minutes of meeting, January 30, 1989.
Recomb DNA Tech Bull. 1989 Jun;12(2):69-134.
3
National Institutes of Health. Points to consider in the design and submission of human somatic-cell gene therapy protocols. Human Gene Therapy Subcommittee, NIH Recombinant DNA Advisory Committee. Adopted September 29, 1986.美国国立卫生研究院。人类体细胞基因治疗方案设计与提交中需考虑的要点。人类基因治疗小组委员会，美国国立卫生研究院重组DNA咨询委员会。1986年9月29日通过。
Recomb DNA Tech Bull. 1986 Dec;9(4):221-42.
4
5
Points to consider in the design and submission of human somatic cell gene therapy protocols.人类体细胞基因治疗方案设计与提交时需考虑的要点。
Recomb DNA Tech Bull. 1985 Dec;8(4):181-6.
6
7
Development of a points to consider document for human somatic cell gene therapy.
Recomb DNA Tech Bull. 1985 Dec;8(4):176-80.
8
NIH guidelines for research involving recombinant DNA molecules.美国国立卫生研究院关于涉及重组DNA分子研究的指南。
Account Res. 1993;3(2-3):177-85. doi: 10.1080/08989629308573848.
9
The revised "Points to Consider" document.修订后的“需考虑要点”文件。
Hum Gene Ther. 1990 Spring;1(1):93-103. doi: 10.1089/hum.1990.1.1-93.
10
Special informed consent requirements are included in protocol review procedures.方案审查程序中包含特殊的知情同意要求。
Hum Res Rep. 1995 Jul;10(7):1-2.
Zotero 插件